767 related articles for article (PubMed ID: 12952227)
21. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
22. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
23. [Changes and clinical significance of CD8(+) T cell subset in patients with aplastic anemia, myelodysplastic syndrome and acute myeloid leukemia].
Zhang JY; Xu HZ; Yin DM; Feng XM; Sui XH; Cui B; Ma CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):203-8. PubMed ID: 23484720
[TBL] [Abstract][Full Text] [Related]
24. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
Huh YO; Jilani I; Estey E; Giles F; Kantarjian H; Freireich E; Albitar M
Leukemia; 2002 Nov; 16(11):2249-52. PubMed ID: 12399969
[TBL] [Abstract][Full Text] [Related]
25. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.
Tamaki H; Ogawa H; Ohyashiki K; Ohyashiki JH; Iwama H; Inoue K; Soma T; Oka Y; Tatekawa T; Oji Y; Tsuboi A; Kim EH; Kawakami M; Fuchigami K; Tomonaga M; Toyama K; Aozasa K; Kishimoto T; Sugiyama H
Leukemia; 1999 Mar; 13(3):393-9. PubMed ID: 10086730
[TBL] [Abstract][Full Text] [Related]
26. Expression and activity of caspases 1 and 3 in myelodysplastic syndromes.
Boudard D; Sordet O; Vasselon C; Revol V; Berthéas MF; Freyssenet D; Viallet A; Piselli S; Guyotat D; Campos L
Leukemia; 2000 Dec; 14(12):2045-51. PubMed ID: 11187891
[TBL] [Abstract][Full Text] [Related]
27. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis.
Mihara K; Chowdhury M; Nakaju N; Hidani S; Ihara A; Hyodo H; Yasunaga S; Takihara Y; Kimura A
Blood; 2006 Jan; 107(1):305-8. PubMed ID: 16160010
[TBL] [Abstract][Full Text] [Related]
28. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
29. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
[TBL] [Abstract][Full Text] [Related]
30. Primary myelodysplastic syndrome: an analysis of 56 patients.
Chen PH; Kuo CY; Huang CH; Shih LY
Changgeng Yi Xue Za Zhi; 1992 Sep; 15(3):121-7. PubMed ID: 1468034
[TBL] [Abstract][Full Text] [Related]
31. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
[TBL] [Abstract][Full Text] [Related]
32. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
33. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A
Eur J Haematol; 1996 Mar; 56(3):124-9. PubMed ID: 8598230
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases.
Foucar K; Langdon RM; Armitage JO; Olson DB; Carroll TJ
Cancer; 1985 Aug; 56(3):553-61. PubMed ID: 3891071
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
[TBL] [Abstract][Full Text] [Related]
36. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.
Mangi MH; Mufti GJ
Blood; 1992 Jan; 79(1):198-205. PubMed ID: 1370203
[TBL] [Abstract][Full Text] [Related]
37. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients.
Maschek H; Gutzmer R; Choritz H; Georgii A
Eur J Haematol; 1994 Nov; 53(5):280-7. PubMed ID: 7813708
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes.
Jacobs RH; Cornbleet MA; Vardiman JW; Larson RA; Le Beau MM; Rowley JD
Blood; 1986 Jun; 67(6):1765-72. PubMed ID: 3708160
[TBL] [Abstract][Full Text] [Related]
39. Myelodysplastic syndrome: a study of prognostic factors.
Lin JS; Lin CK; Liu SM; Chen LY; Wang SY
J Formos Med Assoc; 1991 Mar; 90(3):232-9. PubMed ID: 1677397
[TBL] [Abstract][Full Text] [Related]
40. [Analysis of caspases activity of hematopoietic progenitor cells and its significance in myelodysplastic syndromes].
Chen JL; Xu M; Song XZ; Li Q; Li RS
Zhonghua Xue Ye Xue Za Zhi; 2003 Nov; 24(11):565-7. PubMed ID: 14720439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]